PREPARATION AND EVALUATION OF MULTIPURPOSE METFORMIN HCL GASTRO RETENTIVE DRUG DELIVERY TABLET

Due to its rapid intestinal transit and poor absorption in the upper gastrointestinal tract, metformin, a first-line oral treatment for Type 2 Diabetes Mellitus, has a low bioavailability (~50–60%). Using floating drug delivery system (FDDS) technology, a Gastroretentive drug delivery system (GRDDS) was developed to address these problems. To make tablets that float in stomach fluids, hydrophilic polymers such as Hydroxypropyl Methylcellulose (HPMC K4M) were combined with gas-generating substances like citric acid and sodium bicarbonate. Pre-compression parameters, tablet hardness, and floating lag time were assessed for three formulations (F1–F3). F2 had the best qualities of all of them, including regulated drug release (88.2% over 12 hours), prolonged floating duration (>12 hours), and quick buoyancy (1.6 min). The study found that by keeping the medication in the stomach for a long time, floating metformin tablets present a promising strategy for enhancing therapeutic efficacy, patient compliance, and treatment outcomes for diabetes control.